期刊
ONCOLOGIST
卷 17, 期 12, 页码 1508-1514出版社
OXFORD UNIV PRESS
DOI: 10.1634/theoncologist.2012-0125
关键词
Ketoconazole treatment; Metastatic castration-resistant prostate cancer; Neutrophil-to-lymphocyte ratio; Outcome; Predictive nomogram
类别
Background. The neutrophil-to-lymphocyte ratio (NLR), an inflammation marker, is prognostic in several cancers. We assessed the association between the pretreatment NLR and outcome of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the CYP17 inhibitor ketoconazole. Methods. This was an international, retrospective study of 156 mCRPC patients treated with ketoconazole. The independent effect of the pretreatment NLR and factors associated with treatment outcome were determined by multivariate analysis. Results. Seventy-eight patients (50%) had a >= 50% decline in prostate-specific antigen (PSA). The median progression-free survival (PFS) time was 8 months. Excluded from the analysis were 23 patients without available data on their NLR and those with a recent health event or treatment associated with a blood count change. Sixty-two patients (47%) had a pretreatment NLR > 3. Risk factors associated with the PFS outcome were a pretreatment NLR > 3 and PSA doubling time (PSADT) < 3 months and a prior response to a gonadotropin-releasing hormone agonist of < 24 months or to an antiandrogen of < 6 months. The number of risk factors was used to form a predictive nomogram by patient categorization into favorable (zero or one factor), intermediate (two factors), and poor (three or four factors) risk groups. Conclusions. In mCRPC patients treated with ketoconazole, the pretreatment NLR and PSADT, and prior response to androgen-deprivation therapy, may be associated with the PFS time and used to form a risk stratification predictive nomogram. The Oncologist 2012;17: 1508-1514
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据